SCHEMBL24252342

SCHEMBL24252342

Nc1cnnc2cc(-c3cc(B(O)O)ccc3OC3CCC3)ccc12

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 5/20 0.34
MKNK1 Q9BUB5 2/20 0.32
MKNK2 Q9HBH9 2/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
FEN1 P39748 7/20 0.32
KMO O15229 1/20 0.31
ALOX5AP P20292 5/20 0.31
LRRK2 Q5S007 1/20 0.31
PIM1 P11309 1/20 0.31
PIM3 Q86V86 1/20 0.31
PIM2 Q9P1W9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26771303 0.92 PDE10A (0.35) PDE10AMKNK1MKNK2PDE4APDE4B
SCHEMBL24252661 0.91 TBK1 (0.37) FEN1ALOX5AP
SCHEMBL24252630 0.87 PDE10A (0.31) PDE10A
Formic Acid SCHEMBL25246593 0.87 TBK1 (0.35) FEN1ALOX5AP
Formic Acid SCHEMBL30467611 0.87 TBK1 (0.35) FEN1ALOX5AP
SCHEMBL24252352 0.85 PDE10A (0.32) PDE10A
SCHEMBL30467696 0.85 PDE10A (0.32) PDE10A
SCHEMBL24252296 0.85 PDE10A (0.32) PDE10A
SCHEMBL25212085 0.85 PDE10A (0.32) PDE10A
SCHEMBL24252650 0.84 LRRK2 (0.32) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885MKNK1 3022/4885MKNK2 2673/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDE10A 1950/4885MKNK1 3022/4885MKNK2 2673/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PDE10A 1950/4885MKNK1 3022/4885MKNK2 2673/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PDE10A 2158/4885MKNK1 3311/4885MKNK2 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.